Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.21470/1678-9741-2025-0900 | DOI Listing |
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11771970 | PMC |
Braz J Cardiovasc Surg
January 2025
Coronary Center, Department of Thoracic and Cardiovascular Surgery, Miller Family Heart, Vascular, & Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, United States.
J Thorac Cardiovasc Surg
January 2025
Coronary Center, Department of Thoracic and Cardiovascular Surgery, Miller Family Heart, Vascular, & Thoracic Institute, Cleveland Clinic, Cleveland, Ohio. Electronic address:
Ann Thorac Surg
January 2025
Coronary Center, Department of Thoracic and Cardiovascular Surgery, Miller Family Heart, Vascular & Thoracic Institute, Cleveland Clinic, Cleveland, Ohio. Electronic address:
Eur J Cardiothorac Surg
December 2024
Coronary Center, Department of Thoracic and Cardiovascular Surgery, Miller Family Heart, Vascular, & Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA.
J Surg Oncol
November 2024
Department of Surgical Oncology, PSM unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
The Peritoneal Surface Oncology Group International (PSOGI) previously issued a recommendation endorsing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for treating diffuse malignant peritoneal mesothelioma (DMPM). However, broader acceptance of this approach, particularly within some segments of medical oncology, remains limited. To address this, PSOGI initiated a multisociety consensus effort, involving multidisciplinary International Societies, to strengthen and expand the endorsement of CRS-HIPEC for DMPM.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!